- Home
- ABVX vs CVAC Comparison
ABVX vs CVAC Comparison
Compare ABVX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- CVAC
- Stock Information
- Founded
- ABVX 2013
- CVAC 2000
- Country
- ABVX France
- CVAC Germany
- Employees
- ABVX N/A
- CVAC N/A
- Industry
- ABVX
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ABVX
- CVAC Health Care
- Exchange
- ABVX Nasdaq
- CVAC Nasdaq
- Market Cap
- ABVX 722.3M
- CVAC 637.1M
- IPO Year
- ABVX N/A
- CVAC 2020
- Fundamental
- Price
- ABVX $7.76
- CVAC $2.86
- Analyst Decision
- ABVX Strong Buy
- CVAC Hold
- Analyst Count
- ABVX 6
- CVAC 3
- Target Price
- ABVX $38.67
- CVAC $10.00
- AVG Volume (30 Days)
- ABVX 123.5K
- CVAC 523.1K
- Earning Date
- ABVX 09-09-2024
- CVAC 11-12-2024
- Dividend Yield
- ABVX N/A
- CVAC N/A
- EPS Growth
- ABVX N/A
- CVAC N/A
- EPS
- ABVX N/A
- CVAC N/A
- Revenue
- ABVX $9,676,417.00
- CVAC $70,565,734.00
- Revenue This Year
- ABVX $31.67
- CVAC $738.59
- Revenue Next Year
- ABVX $1,189.66
- CVAC N/A
- P/E Ratio
- ABVX N/A
- CVAC N/A
- Revenue Growth
- ABVX 100.87
- CVAC 75.11
- 52 Week Low
- ABVX $7.11
- CVAC $2.22
- 52 Week High
- ABVX $17.02
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- ABVX 40.45
- CVAC 46.81
- Support Level
- ABVX $7.11
- CVAC $2.85
- Resistance Level
- ABVX $8.18
- CVAC $3.56
- Average True Range (ATR)
- ABVX 0.44
- CVAC 0.17
- MACD
- ABVX -0.00
- CVAC -0.01
- Stochastic Oscillator
- ABVX 44.24
- CVAC 14.56
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.